Nyhet - 25 Maj 2021 00:00

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine

Ämnen

OnDosis – Changing the game, one dose at a time

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Ämnen

Kontakter

Martin Olovsson

OnDosis – Changing the game, one dose at a time